Items tagged with HIV coinfection
Global Fund Observer special edition on Ukraine: 31 March 2022 (post)
Aidspan published a special issue of the Global Fund Observer, covering aspects of the Ukrainian-Russian conflict and its impact, both domestic and beyond. It particularly focuses on maintaining essential live-saving services for HIV and TB.
All HIV patients should be tested for TB in high-burden areas (post)
The meta-analysis included 6 studies, of which 5 were conducted in sub-Saharan Africa, showed that the diagnostic accuracy for Xpert testing was similar to the former symptom screening and rapid test format.
Incident TB in one in three people starting antiretroviral therapy in Thailand (post)
A study from Thailand has found that the incidence of tuberculosis was remarkably high among people with HIV during the first year on antiretroviral therapy, and thereafter, decreased significantly until reaching levels comparable to those in the Thai general population after ten years. The study, published in a recent issue of the Journal of the International AIDS Society, is important as it is most probably the first to report such data from a high TB/HIV burden country in Asia.
Report from the scoping consultation on severe bacterial infections among people with advanced HIV disease (post)
The World Health Organization (WHO) convened a scoping consultation on severe bacterial infections (SBIs) in advanced HIV disease (AHD), consulting with academics, program managers and civil society representatives.
Blood-based biomarkers as a promising tool for early detection of incipient TB in people living with HIV (post)
According to the World Health Organization (WHO), one-quarter of the world's population is estimated to be infected by TB bacteria, Mycobacterium tuberculosis (MTB), which can cause tuberculosis (TB). Although it is preventable and curable, 1.5 million people die from the infectious lung disease each year. TB is also a leading cause of death for people living with HIV. Most people infected with TB bacteria remain in a stage of latent TB and never develop TB disease. However, about 5 to 15% of people with latent TB may develop active TB disease in the future and potentially spread it to others. As X-ray and CT diagnostics are too unspecific for early and accurate detection of subclinical TB disease, there are to date no diagnostic tools to assess TB disease activity in living patients during clinically latent TB or during a HIV/TB coinfection.
Dolutegravir twice-daily dosing in children with HIV-associated TB: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial (post)
Children with HIV-associated TB have few antiretroviral therapy options. A study, published in The Lancet HIV, evaluated the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
CHAI publishes 2022 Advanced HIV Disease Impact Report (post)
The Clinton Health Access Initiative (CHAI) published the Advanced HIV Disease (AHD) Impact Report, which provides a detailed look at progress made since 2019 to avert preventable deaths among people with AHD, best practices for AHD program implementation, and CHAI’s perspective of what more will be needed to effectively end deaths from AHD-related opportunistic infections.
South Africa regresses in efforts to protect people with HIV from TB (post)
SA’s progress in expanding access to PrEP is one of the few positive findings in the latest global AIDS report.
Oral six-month treatment for MDR-TB is safe and effective in people with HIV (post)
An all-oral treatment regimen for multidrug-resistant tuberculosis (MDR-TB) recently recommended as a new standard of care by the World Health Organization is effective and safe in people living with HIV, Dr Ilaria Motta of Médecins sans Frontières reported at the 24th International AIDS Conference (AIDS 2022) in Montreal.
What will it take to end advanced HIV disease-related deaths? (post)
“A key point when thinking about how to reduce AIDS-related mortality is to recognise that while scale-up of antiretroviral therapy (ART) is absolutely necessary for decreasing deaths, ART alone is not sufficient to achieve mortality reduction targets,” Dr Laura Broyles from the Global Health Impact Group told the International AIDS Conference (AIDS 2022) in Montreal, Canada, held on 29 July - 2 August 2022. The leading cause of mortality among people with advanced HIV disease are two treatable opportunistic infections: TB and cryptococcal meningitis.
Page 39 of 52 · Total posts: 0
←First 38 39 40 Last→